3 May 2024
Researchers from ß÷ß÷Ö±²¥ have received more than $41 million through the (NHMRC) to address health challenges.
The 24 ß÷ß÷Ö±²¥ researchers will lead projects from the development of pain killers and anti-epileptic drugs using venom, to improving patient outcomes for ovarian, endometrial and thyroid cancers.
The Investigator Grants program is the NHMRC’s largest funding scheme, enabling researchers to advance projects across biomedical, clinical, public health and health services research.
2024 ß÷ß÷Ö±²¥ Investigator Grants recipients:
- will lead research to identify the genetic defects that increase the risk of oesophageal cancer.
- will lead research to inform the development of therapies for autoimmune disease.
- will explore opportunities to use artificial intelligence and social media to reduce youth vaping.
- will lead research to improve understanding about the impact of mobile DNA on neurodegenerative diseases and brain cell death.
- will co-design healthy food retail policies to improve nutrition and reduce chronic disease in remote Indigenous communities.
- will lead research to improve understanding on how disruptions to the circadian rhythm impacts on liver and metabolic diseases.
- will lead research to improve First Nations cancer treatment outcomes for patients and carers, including preventative screening programs and end-of-life care.
- will lead research to improve understanding on the use of low-intensity ultrasound to treat brain diseases such as Alzheimer’s.
- will lead the development of a diagnostic tool to improve treatment for patients with life-threatening and drug-resistant blood infections.
- will lead research to inform non-invasive treatment options for gum disease.
- will lead research to strengthen understanding of how the white blood cell protein Interleukin-22 can improve liver health.
- will lead research to inform targeted melanoma screening for individuals at high risk.
- will lead research into the causes of ovarian, endometrial and thyroid cancers to improve prevention and patient outcomes.
- will lead the development of pain killers and anti-epileptic drugs using animal venom.
- will lead the development of detection technology to identify patients at early-stage risk of cancer.
- will lead the development of a digital resource hub to improve understanding of frailty using education modules and goal-setting activities to prevent and manage decline in cognitive and physical capacity.
- will lead research to inform therapeutic strategies to reduce age-onset disease.
- will lead research to inform control and prevention strategies for priority infectious diseases in Australia and Pacific Islands.
- will lead the development of an oral-vaccine delivery platform to improve treatment of infectious and chronic diseases.
- will lead research to strengthen understanding of melanoma development where there isn’t a preexisting mole on the skin.
- will lead research to reduce inflammation and nerve damage following cancer therapy.
- will lead research to improve health outcomes for elderly Australians with communication disorders through improved quality of care, training and resources.
- will lead research to inform antibiotic-free therapeutic strategies to reduce severity of bacterial infections.
- will lead the development of digital nanotechnology to detect weakened immune system regulation caused by long COVID.
Media contact
ß÷ß÷Ö±²¥ Communications
+61 429 056 139
